The National Institute on Deafness and Other Communication Disorders (NIDCD), a member of the U.S. NIH to provide Remmie Health with nearly $3 million in support, subject to the availability of fundsSEATTLE, June 12, 2024 /PRNewswire/ -- Remmie Health has been awarded a Small Business Innovation Research (SBIR) Phase 2 grant to develop and commercialize Remmie.ai, an AI-based diagnostic assistance engine for supporting clinicians to accurately identify ENT diseases.

美国国立卫生研究院耳聋和其他沟通障碍研究所（NIDCD）是美国国立卫生研究院（NIH）的一名成员，该研究所将为Remmie Health提供近300万美元的支持，前提是fundsSEATTLE的可用性，2024年6月12日/PRNewswire/--Remmie Health已获得小型企业创新研究（SBIR）第二阶段拨款，用于开发和商业化Remmie.ai，这是一种基于人工智能的诊断辅助引擎，用于支持临床医生准确识别耳鼻喉科疾病。

The National Institute on Deafness and Other Communication Disorders (NIDCD), a member of the U.S. National Institutes of Health (NIH), plans to provide nearly $3 million in support, subject to the availability of funds..

美国国立卫生研究院（NIH）成员之一的国家耳聋和其他沟通障碍研究所（NIDCD）计划根据资金的可用性提供近300万美元的支持。。

Continue Reading

继续阅读

According to Jane Zhang, PhD/MBA, Remmie's CEO and President, 'This NIH SBIR Phase 2 grant is a milestone in AI healthcare, enabling more accurate and efficient diagnostic assistance tools for ENT conditions, addressing the $40 billion global market for accurate ENT diagnosis. This will ultimately help increase access, reduce costs, and enhance confidence in diagnosis and referral care for patients worldwide.'.

据Remmie首席执行官兼总裁Jane Zhang博士/工商管理硕士说，“这项NIH SBIR第二阶段拨款是人工智能医疗保健的一个里程碑，为耳鼻喉科疾病提供了更准确和高效的诊断辅助工具，为全球400亿美元的耳鼻喉科准确诊断市场提供了帮助。这最终将有助于增加获取机会，降低成本，并增强全球患者对诊断和转诊护理的信心。”。

ENT diagnosis depends upon in-person clinic visits and visual examination by medical providers, at great inconvenience to patients and caregivers and a significant cost to the healthcare system, estimated at $4 billion per year.

耳鼻喉科的诊断取决于医疗服务提供者的亲自就诊和视觉检查，给患者和护理人员带来极大不便，并给医疗保健系统带来巨大成本，估计每年40亿美元。

'This grant is a milestone in AI healthcare, enabling more accurate and efficient diagnostic assistance tools for ENT conditions, addressing the $40 billion global market for accurate ENT diagnosis,' said Jane Zhang, PhD/MBA, Remmie's CEO and President. 'This will ultimately help increase access, reduce costs, and enhance confidence in diagnosis and referral care for patients worldwide.'.

Remmie首席执行官兼总裁张珍（Jane Zhang）博士/工商管理硕士（MBA）说，这笔赠款是人工智能医疗保健领域的一个里程碑，为耳鼻喉科疾病提供了更准确和高效的诊断辅助工具，为全球400亿美元的耳鼻喉科准确诊断市场提供了帮助这最终将有助于增加获取机会，降低成本，并增强全球患者对诊断和转诊护理的信心。”。

The grant encompasses clinical research with Ann & Robert H. Lurie Children's Hospital of Chicago, one of the top children's hospitals in the nation. Led by Dr. Juan Espinoza, the study team will include key members of the Medical Device Clinical Trials Unit for The Consortium for Technology & Innovation in Pediatrics (CTIP), an FDA-funded pediatric device accelerator centered at Lurie Children's, the Division of Otorhinolaryngology - Head and Neck Surgery, and the Smith Child Health Catalyst, a research service core at the intersection of pediatric research and child health.'Remmie.ai's preliminary data are compelling, and we are confident in our ability to explore its clinical applications and develop this innovative technology for pediatric care,' says Juan Espinoza, MD, Chief Research Informatics Officer of Stanley Manne Children's Research Institute at Lurie Children's, and CTIP Director. This award builds on last year's SBIR Phase 1 success, where Remmie.ai achieved high accuracy in recognizing both binary and multi-class ear conditions and deployed for usability feedback. The two-year Phase 2 will advance Remmie.ai's development and integration into clinical practice.

该资助包括与美国顶尖儿童医院之一的芝加哥安与罗伯特·H·卢里儿童医院进行的临床研究。在胡安·埃斯皮诺扎博士的领导下，研究团队将包括儿科技术与创新联盟（CTIP）医疗器械临床试验部门的关键成员，CTIP是一家由FDA资助的儿科设备加速器，中心位于卢里儿童医院（Lurie Children's），耳鼻咽喉头颈外科（耳鼻咽喉头颈外科），以及史密斯儿童健康催化剂（Smith Child Health Catalyst），这是儿科研究和儿童健康交叉点的研究服务核心。”路易儿童医院斯坦利·曼恩儿童研究所首席研究信息官兼CTIP主任胡安·埃斯皮诺扎（JuanEspinoza）医学博士说，人工智能的初步数据令人信服，我们有信心探索其临床应用并开发这种儿科护理创新技术。该奖项建立在去年SBIR第一阶段成功的基础上，Remmie.ai在识别二进制和多类ear条件方面取得了很高的准确性，并部署用于可用性反馈。为期两年的第二阶段将促进Remmie.ai的发展并将其融入临床实践。

The outcomes will deliver accurate ENT diagnosis assistance through real-world testing and lead towards FDA designation as a Software as Medical Device (SaMD).For more information about Remmie, visit https://remmiehealth.com/remmie-ai. For investment and healthcare partnerships, click here to contact Remmie Health CEO, Jane Zhang.About Remmie:Remmie helps families play a more active role in their health from the convenience of home by bringing connected ENT examinations into their hands to share with a doctor online.

该结果将通过实际测试提供准确的耳鼻喉科诊断帮助，并导致FDA将其指定为医疗器械软件（SaMD）。有关Remmie的更多信息，请访问https://remmiehealth.com/remmie-ai.有关投资和医疗保健合作关系，请单击此处联系Remmie Health首席执行官Jane Zhang。关于Remmie：Remmie通过将连接的耳鼻喉科检查带到他们手中，与在线医生分享，帮助家庭从家庭的便利中发挥更积极的健康作用。

Remmie uses technology to target the most common reason Americans go to the doctor'.

雷米利用技术瞄准美国人最常见的看病原因。